香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 证券代码：300347 证券简称：泰格医药 公告编码（2025）030 号 杭州泰格医药科技股份有限公司 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年7月17日 於 本 公 告 日 期，執 行 董 事 為 ...

Corporate Announcements - Helen Piano's actual controllers are planning a change in control, leading to a suspension of trading starting July 18, 2025, for up to 2 trading days [3] - Tiger Med is selling 95.09% of its stake in Lixin Pharmaceutical to Charoen Pokphand Group for approximately $34.11 million [4] - Stik's wholly-owned subsidiary plans to invest about 509 million yuan in expanding high-end functional film production [5] - Oriental Yuhong's wholly-owned subsidiaries intend to acquire 100% of Chile's Construmart for approximately $123 million, which operates around 31 building material supermarkets [6] Performance Reports - Hangzhou Bank reported a net profit of 11.662 billion yuan for the first half of 2025, a year-on-year increase of 16.67% [8] - Tuojing Technology expects a net profit increase of 101% to 108% for Q2 2025, with revenue projected between 1.21 billion to 1.26 billion yuan [9] - Microchip Biotech anticipates a net profit of 30.06 million yuan for H1 2025, reversing a loss from the previous year, driven by increased sales of specific products [10] - Zhongwei Company expects a net profit increase of 31.61% to 41.28% for H1 2025, with revenue around 4.961 billion yuan [12] - Qianyuan Power reported a net profit of 12.7 million yuan for H1 2025, a decrease of 4.54% year-on-year [13] - Xiamen Tungsten's net profit for H1 2025 was 972 million yuan, down 4.41% year-on-year, attributed to the absence of significant investment gains from the previous year [14] Major Contracts - State Grid Information Technology announced winning contracts totaling 966 million yuan from the State Grid Corporation for equipment procurement [16] - Beizhi Technology signed a contract worth 164 million yuan with Jushi Group for equipment procurement [17] - Mould Technology received a project letter for exterior parts from a luxury car client, with expected total sales of 2.044 billion yuan over five years [18] Shareholder Actions - Huasheng Lithium Battery's shareholder plans to reduce holdings by up to 2.24% of the company's total shares [20] - Hongta Securities intends to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 12.76 yuan per share [22]

证券代码：300347 证券简称：泰格医药 公告编码（2025）031 号 杭州泰格医药科技股份有限公司 关于出售参股公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、交易背景 2019年12月，经杭州泰格医药科技股份有限公司（以下简称"公司"）董事长审议 批准，公司所属投资平台杭州泰格股权投资合伙企业（有限合伙）（以下简称"泰格股 权"）取得礼新医药科技（上海）有限公司（以下简称"礼新医药"或"标的公司"） 4.762%的股权。经公司董事长审议批准，公司分别于2020年5月和11月签署追加投资认 购协议，通过泰格股权以自有资金分别追加投资1,000万人民币和4,000万人民币认购礼 新医药新发行的2.86%以及2.65%股权。 以上投资事项均不构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，无需提交董事会审批，公司已履行相应的内部审批程序。 截至本公告披露日，公司通过泰格股权直接持有礼新医药股权比例为3.41%；通过 持有基金等份额穿透后间接持有礼新医药股权比例为4.58%。公司在礼新医药无董事席 位。 二、本次交 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）030 号 1 大制药"或"买方"）。公司作为礼新医药参股股东，在全面分析创新药市场、标的公司的 核心技术和经营情况后，拟同意标的公司的出售安排，配合其将泰格股权直接持有礼新医 药的全部股权以对价约3,411万美元转让给买方，并签署相关交易文件。 杭州泰格医药科技股份有限公司 第五届董事会第十七次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十七次会议于2025 年7月17日在杭州市滨江区聚工路19号盛大科技园A座18层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2025年7月15日以电话、电子邮件方式向全体董 事发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次会议 的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于出售参股公司股权的议案》。 2019年12月，经杭州泰 ...

智通财经7月17日电，泰格医药(300347.SZ)公告称，公司通过泰格股权直接持有礼新医药股权比例为 3.41%；通过持有基金等份额穿透后间接持有礼新医药股权比例为4.58%。礼新医药拟将95.09%股权转 让给正大制药投资（北京）集团有限公司。公司拟同意标的公司的出售安排，配合将泰格股权直接持有 的礼新医药全部股权以约3,411万美元转让给买方。本次交易完成后，公司将不再持有礼新医药的股 权。 泰格医药：出售参股公司礼新医药股权 ...

Core Viewpoint - Tiger Medical (300347) announced that its investment platform, Tiger Equity, acquired a 4.762% stake in Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. and made additional investments of 10 million RMB and 40 million RMB to subscribe for newly issued shares of 2.86% and 2.65% respectively [1] Group 1 - As of the announcement date, Tiger Medical directly holds 3.41% of Lixin Pharmaceutical's equity through Tiger Equity, and indirectly holds 4.58% through fund shares [1] - Lixin Pharmaceutical plans to transfer 95.09% of its equity to Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd., and Tiger Medical agrees to sell all its holdings for approximately 34.11 million USD [1] - This transaction is expected to enhance cash income, supplement cash flow, and promote the sustainable and healthy development of the company while maximizing shareholder value [1]

Group 1 - The innovative drug sector in A-shares and Hong Kong stocks has seen significant gains, with the Tianhong Innovative Drug ETF (517380) rising by 3.63% and many constituent stocks, such as Sangfor and Kexing, increasing by over 10% [1] - The Tianhong Innovative Drug ETF (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and tracks the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index, which has a cumulative weight of nearly 60% in its top ten constituent stocks [1] - The Biopharmaceutical ETF (159859) also experienced a rise of 1.28%, with a trading volume exceeding 95 million yuan, and notable gains in constituent stocks like Shenzhou Cell and Anke Bio [1][2] Group 2 - The biopharmaceutical ETF (159859) closely tracks the National Securities Biopharmaceutical Index and is currently the largest in its category [2] - A cooperation agreement was signed between the Hunan Provincial Government and the National Administration of Traditional Chinese Medicine to build a national Chinese medicinal material germplasm resource bank, which aims to enhance the sustainable development of traditional Chinese medicine resources [2] - The innovative drug sector remains a key investment focus, driven by improved biotech financing and supportive domestic policies, alongside the positive earnings forecast from WuXi AppTec [2][3] Group 3 - The innovative drug sector's sustainability is supported by ongoing policy backing, enhanced global competitiveness, and the realization of commercial profits [3] - There is a focus on the improving fundamentals of the innovative drug industry chain, with recovery trends observed in overseas orders and domestic business autonomy [3]

Group 1 - The China Securities Hong Kong Stock Connect Medical Theme Index (932069) has seen a strong increase of 2.89%, with notable gains in constituent stocks such as Kangfang Biotech (09926) up 10.16%, BeiGene (06160) up 9.17%, and Kelun-Biotech (06990) up 8.05% [1][2] - The Hong Kong Medical ETF (159366) has risen by 2.00%, marking its third consecutive increase, with the latest price reaching 1.38 HKD, a new high [1][2] - The index reflects the performance of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology within the Hong Kong Stock Connect framework [6] Group 2 - The 2025 National Basic Medical Insurance and other insurance drug directories have officially started adjustments, with the first addition of innovative drugs to the commercial health insurance directory this year [3] - WuXi AppTec has disclosed a positive half-year performance forecast for 2025, exceeding market expectations, leading to a collective rise in the CXO sector [4] - The AI medical technology sector is transitioning towards multi-modal integration, significantly enhancing the intelligence level in medical scenarios, with AI-assisted diagnosis systems penetrating 89% of top-tier hospitals [4] Group 3 - The medical device and traditional Chinese medicine sectors are expected to see a performance turning point in the second half of 2025, with a focus on new technology directions such as medical devices, AI healthcare, and brain-computer interfaces [5] - The Hong Kong Medical ETF aggregates rare and specialized medical segment leaders from the mainland, focusing on internet healthcare, CXO, and medical devices [5] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 57.7% of the total, including companies like WuXi Biologics (02269) and JD Health (06618) [6]

Group 1 - Hong Kong biopharmaceutical stocks experienced an initial surge, with 康方生物 (09926.HK) rising over 8% [1] - 泰格医药 (03347.HK) increased by more than 4% [1] - 百济神州 (06160.HK) and 复宏汉霖 (02696.HK) both saw nearly 4% gains [1] - 金斯瑞生物科技 (01548.HK) rose by over 3% [1]

Group 1 - The report analyzes the strategic management of market capitalization for A-share pharmaceutical and biotechnology companies in 2024, indicating a rebound in the industry but a slow recovery of indices, with a total market capitalization of 6.6 trillion yuan, accounting for 6.62% of A-shares [1][19][22] - The industry is characterized by "low profit, high P/E ratio," but the "high valuation" feature is weakening, with the overall score for value creation at 45.65, below the levels of 2022-2023 [1][25][14] - The report highlights six core areas of regulatory focus to support innovative drugs, emphasizing the need for innovation-driven changes in market structure and industry transformation, with record approvals for innovative drugs and devices [1][16][17] Group 2 - The essence of market capitalization management is to "create value and raise expectations," with a focus on value creation, shaping, and management, indicating a need for companies to optimize strategies to enhance market performance [1][32][14] - The report provides recommendations for market capitalization management, including solidifying value foundations, refining investment value labels, and enriching management tools, while noting significant challenges and clear differentiation within the industry [2][15] - The report identifies a need for improved communication and compliance in investor relations to stabilize market expectations, as overall performance growth and investment return certainty are declining [15][46][47]